➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 7,704,995

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,704,995
Title:Protein kinase modulators and methods of use
Abstract: This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.
Inventor(s): Buhr; Chris A. (Redwood City, CA), Baik; Tae-Gon (Foster City, CA), Ma; Sunghoon (Foster City, CA), Tesfai; Zerom (Castro Valley, CA), Wang; Longcheng (Palo Alto, CA), Co; Erick Wang (Redwood City, CA), Epshteyn; Sergey (Fremont, CA), Kennedy; Abigail R (San Leandro, CA), Chen; Baili (Palo Alto, CA), Dubenko; Larisa (San Francisco, CA), Anand; Neel Kumar (San Mateo, CA), Tsang; Tsze H. (El Cerrito, CA), Nuss; John M. (Danville, CA), Peto; Csaba J (Alameda, CA), Rice; Kenneth D. (Mill Valley, CA), Ibrahim; Mohamed Abdulkader (Mountain View, CA), Schnepp; Kevin Luke (Elk Grove, CA), Shi; Xian (San Francisco, CA), Leahy; James William (San Leandro, CA), Chen; Jeff (San Francisco, CA), Dalrymple; Lisa Esther (San Francisco, CA), Forsyth; Timothy Patrick (San Mateo, CA), Huynh; Tai Phat (Oakland, CA), Mann; Grace (Brisbane, CA), Mann; Larry Wayne (Redwood City, CA), Takeuchi; Craig Stacy (Burlingame, CA), Lamb; Peter (Oakland, CA), Matthews; David J. (San Francisco, CA), Miller; Nicole (San Francisco, CA)
Assignee: Exelixis, Inc. (South San Francisco, CA)
Application Number:10/513,081
Patent Claims:see list of patent claims

Details for Patent 7,704,995

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Exelixis, Inc. (South San Francisco, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,704,995

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.